Cybin (CYBN.NE) announced it has filed their 13th provisional patent application and is building out its digital therapeutics strategy.
Cybin did not go into detail about the patent application, but they did note that the subject of the patent application is its digital therapeutics strategy. In its press release, CYBN said it is “evolving its programs beyond the psychedelic molecule, into an eco-system that may potentially drive improved patient treatments through the advancement of its digital therapeutics development.”
The digital therapeutics will be led by Cybin’s innovation team, including its newly formed patient steering committee. This represents a new phase of CYBN’s digital therapeutics platform, which it believes will better enable the evaluation of patient outcomes. The platform will use a secure data analytics platform for better pre and post-psychedelic treatments. This will allow better assessment for patients, and it could also enable those who live further away from health care professionals or who have busier schedules to have better access to mental health assessment.
During the pandemic, there has been a big move towards telemedicine and digital healthcare, and I’ve personally been very sceptical of a lot of the changes.
During the pandemic, there has been a big move towards telemedicine and digital healthcare, and I’ve personally been very sceptical of a lot of the changes. A lot of medical evaluation needs to be done in person, in my opinion, but mental health assessment is the one exception. Freudian psychoanalysts may have once thought you had to pick up on subtle clues from a person’s body language to know what was going on in their subconscious, but now most professionals realize that the most effective treatment comes from just listening to what people have to say, something that can be done easily over a video call.
Cybin said it is building “an advanced eco-system that can drive innovation from the psychedelic molecule, delivery of the molecule, quantitative testing of the molecule in patients to late-stage trials and one day potential patient treatments.”
This move should not be seen in isolation, however. Cybin said it is building “an advanced eco-system that can drive innovation from the psychedelic molecule, delivery of the molecule, quantitative testing of the molecule in patients to late-stage trials and one day potential patient treatments.” This eco-system includes recently announced partnerships with Greenbrook TMS, who CYBN is joining forces with to create Mental Health Centers of Excellence, and Kernel, whose cerebral cortex hemodynamics measurement study Cybin is sponsoring.
Having effective telemedicine capabilities will also improve Cybin’s research and study recruitment abilities. If people only have to come into their clinic once for the actual treatment, rather than for every single check-in, then they can recruit people who may live further from the clinics, and for those they do recruit who live further away, they may be able to schedule more regular check-ups, allowing them to gather more, and better, data during their research.
Following the news, Cybin continues its recent gains by seeing its shares up 15 cents and is currently trading at $3.74.
Full disclosure: Cybin is an Equity Guru marketing client.
